 |
| (사진= HLB) |
[Alpha Biz=(Chicago) Reporter Paul Lee] The combination therapy of HLB's targeted anticancer drug "Rivoceranib" and China's Jiangsu Hengrui Medicine's immuno-cancer drug "Camrelizumab" has been approved as the primary treatment for liver cancer in China. Following China, HLB and Jiangsu Hengrui Medicine will also apply for approval from the U.S. Food and Drug Administration (FDA) within this year.
The HLB announced on the 1st that the Shanghai Stock Exchange in China approved a combination therapy of "Rivoceranib+Camrelizumab" as the primary treatment for liver cancer by the Chinese National Drug Supervision Administration (NMPA) the previous day. It has been about three years and nine months since the third phase of global clinical trials began in April 2019. It is the fifth new drug as a primary treatment for liver cancer in China.
The HLB believes that the combination of rivoceranib+camrelizumab can expand treatment options and reduce costs. In particular, it focuses on the approval of the US FDA. In order to increase its market share in the early stages of its launch, the company plans to conduct direct sales in the U.S. and export technologies to European and Asian countries along with the licensing process.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
